# Stephen Thomas

> Stephen Thomas is a chemist and company founder who serves as CEO and director of Sera Medicines, co-founder and director of Navigator Medicines, and a board member of Climb Bio. His career includes scientific leadership at Ichorion, Cerecor and ValenzaBio and the CEO role at Tenet Medicines before its acquisition by Eliem. He trained at Rensselaer Polytechnic Institute and Columbia University.

- **Role:** CEO and Director at Sera Medicines; Co-Founder and Director at Navigator Medicines
- **Organizations:** Sera Medicines, Navigator Medicines, Climb Bio, Starfish Medicines, Tenet Medicines, ValenzaBio, Cerecor (now Avalo Therapeutics), Ichorion Therapeutics
- **Nationality:** American
- **Education:** B.S. in Chemistry, Rensselaer Polytechnic Institute, M.S. in Chemistry (Organic Synthesis), Columbia University, Ph.D. in Chemistry (Organic Synthesis and Chemical Biology), Columbia University
- **Known for:** Co-founded Ichorion Therapeutics, later acquired by Cerecor., Co-founded and led Tenet Medicines before its acquisition by Eliem., Co-founded Navigator Medicines, which announced a $100 million Series A in August 2024.

## Career timeline

- **2010** — Graduated from Rensselaer Polytechnic Institute and headed to Columbia for graduate study.
- **Before September 2018** — Co-founded Ichorion Therapeutics and served as chief scientific officer.
- **2018-09 to 2020-02** — Vice President and Head of Discovery at Cerecor following its acquisition of Ichorion.
- **2020-02 to 2023-01** — Chief Scientific Officer at ValenzaBio, acquired by Acelyrin in January 2023.
- **2023-11 onward** — CEO and director of Sera Medicines.
- **2023-11 to 2024-06** — CEO and director of Tenet Medicines, which he co-founded; Eliem acquired Tenet in June 2024.
- **2024-06 onward** — Joined the board of Eliem Therapeutics, subsequently renamed Climb Bio.
- **2024-03** — Began serving as CEO and director of Starfish Medicines, according to Climb’s 2025 proxy.
- **2024-08 to 2025-02** — Served as CEO of Navigator Medicines, which he co-founded; continues as director.

## Achievements

- Co-founded Ichorion Therapeutics, later acquired by Cerecor.
- Co-founded and led Tenet Medicines before its acquisition by Eliem.
- Co-founded Navigator Medicines, which announced a $100 million Series A in August 2024.
- NSF Predoctoral Fellow and Bristol-Myers Squibb Graduate Fellow at Columbia.
- Former Amgen Scholar.
- Pegram Award for Meritorious Achievement in Chemical Research, listed on his LinkedIn profile (2015).

## Latest updates

- **2026-04** — Climb Bio’s definitive proxy lists Thomas as Sera CEO and director, Navigator director and a Climb board member; it confirms his Navigator CEO tenure ended in February 2025.

## Links

- Website: https://www.seramedicines.com/stephen-thomas
- LinkedIn: https://www.linkedin.com/in/stephen-thomas-1a265946

---

Profile page: https://yespress.io/stephen-thomas
Published by YesPress — https://yespress.io
Last updated: 2026-10-25